{"product_id":"pitobrunib-pirtobrutinib","title":"Pitobrunib (Pirtobrutinib)","description":"\u003ch2\u003e\u003cspan id=\"About_Pirtobrutinib\"\u003eAbout Pirtobrutinib \u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003ePirtobrutinib is an inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK).\u003csup id=\"cite_ref-Aslan_2022_5-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Mantle_Cell_Lymphoma\"\u003eMantle Cell Lymphoma\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated for relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Chronic_Lymphocytic_LeukemiaSmall_Lymphocytic_Lymphoma\"\u003eChronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated for chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) in adults who have received at ≥2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eAsymptomatic lymphocytosis: Dose modification not recommended\u003c\/p\u003e\u003cp\u003eAsymptomatic lipase increase: May not necessarily warrant a dose modification\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Hematologic_toxicities\"\u003eHematologic toxicities\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eNOTE: Based on starting dose of 200 mg qDay\u003c\/li\u003e\n\u003cli\u003eAbsolute neutrophil count (ANC) 0.5 to \u0026lt;1 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with fever and\/or infection\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;0.5 x 10\u003csup\u003e9\u003c\/sup\u003e\/L lasting ≥7 days\u003c\/li\u003e\n\u003cli\u003ePlatelet count 25 to \u0026lt;50 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with bleeding\u003c\/li\u003e\n\u003cli\u003ePlatelet count \u0026lt;25 x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\n\u003cli\u003e\n\u003ch3\u003e\u003cspan id=\"Modification\"\u003eModification\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at original dose (200 mg qDay)\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 50 mg qDay\u003c\/li\u003e\n\u003cli\u003eFourth occurrence: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797956522027,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-283.png?v=1787022262","url":"https:\/\/xomeds.com\/products\/pitobrunib-pirtobrutinib","provider":"XOMEDS","version":"1.0","type":"link"}